



1632/\$
Psh

PTO/SB/21 (04-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/806,110
	Filing Date	August 21, 2001
	First Named Inventor	KARAPLIS, Andrew C.
	Art Unit	1632
	Examiner Name	SHUKLA, Ram R.
Total Number of Pages in This Submission	Attorney Docket Number	1770-214US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Roula Thomas Ogilvy Renault
Signature	<i>R Thomas</i>
Date	Aug 19, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	
Signature	Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



File No.: 1770-214US

August 18, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: KARAPLIS, Andrew C. et al.
Filed: 31 August 2001
Serial No.: 09/806,110
Title: USE OF PEX IN THE TREATMENT OF
METABOLIC BONE DISEASES
Examiner: SHUKLA, Ram R.
Group Art Unit: 1632

Mail Stop Amendment
Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A.

Sir:

INFORMATION DISCLOSURE STATEMENT
FEE REQUIRED

Pursuant to the duty of disclosure under 37 CFR 1.56, copies of the references listed on the attached PTO Form 1449 are submitted herewith.

The Commissioner is hereby authorized to charge the fee of \$180.00 for late submission of this Information Disclosure Statement in accordance with 37 CFR 1.97(c), any additional fees which may be required, or credit any overpayment to our Account No. 19-5113.

In accordance with 37 CFR 1.97(h), the submission of the present information is not to be construed as an admission that such information is, or is considered to be material to patentability.

08/20/2004 GWORDOF1 00000057 195113 09806110

01 FC:1806 180.00 DA

Commissioner of Patents and Trademarks
United States Patent Application No. 09/806,110

The Examiner is kindly requested to consider the references submitted during the examination of the above-identified application, making the references of record, and to return an initialed copy of the PTO-1449 Form to the below-signed agent.

Respectfully submitted,
KARAPLIS, Andrew C. et al.



Roula Thomas
Agent of Record, Registration No. 54,907
OGILVY RENAULT
1600 - 1981 McGill College Avenue
Montreal, Quebec, Canada H3A 2Y3

Encl. Form PTO-1449

Sheet 1 of 1

Form PTO-1449 (Rev.7-80)	U.S. Department of Commerce Patent & Trademark Office	ATTY.DOCKET NO. SWA-006US1 (1011/007)	SERIAL NO. 09/806,110
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Karaplis, Andrew C. et al.	
		FILING DATE: August 31, 2001	GROUP 1632

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	AA						
	AB						
	AC						
	AD						
	AF						
	AF						
	AG						
	AH						
	AF						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document number	Date	Country	Class	Subclass	Translation
	AL						
	AM						
	AN						
	AO						
	AP						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Kiebzak et al. <i>Secondary Hyperparathyroidism in X-linked Hypophosphatemic Mice</i> , Endocrinology, 1982 Aug; 111(2); 650-652.
	AS	Blydt-Hansen et al. <i>PHEX Expression in Parathyroid Gland and Parathyroid Hormone Dysregulation in X-linked Hypophosphatemia</i> , Pediatr. Nephrol, 1999, 13:607-677.
	AT	

Examiner	Date considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	